Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Ming‐kang Zhong"'
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background and purpose: Testosterone is an essential sex hormone in maintaining masculine characteristics, which is prescribed for male hypogonadism as testosterone replacement treatment (TRT). Herein, we investigated long-standing controversies abou
Externí odkaz:
https://doaj.org/article/dedd46f3612c41d7895fcb9c0bd29965
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background and purpose: Several clinical trials have indicated that the use of canagliflozin increases the risk of lower extremity amputation. Although the US Food and Drug Administration (FDA) has withdrawn its black box warning about amputation ris
Externí odkaz:
https://doaj.org/article/9335d3548dcd495b938a73f71cefe71d
Autor:
Ming-Ming Yan, Hui Zhao, Zi-Ran Li, Jun-Wei Chow, Qian Zhang, Yu-Peng Qi, Shu-Shan Wu, Ming-Kang Zhong, Xiao-Yan Qiu
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background and purpose: Serious adverse events following immunization (AEFI) associated with the COVID-19 vaccines, including BNT162b2 (Pfizer-BioNTech), Ad26.COV2.S (Janssen), and mRNA-1273 (Moderna), have not yet been fully investigated. This study
Externí odkaz:
https://doaj.org/article/b5b0594f86a2472d82955a4854c0624d
Publikováno v:
BMJ Open, Vol 12, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/542c2a663cf74332bcdfd2b7ea86b0f9
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Introduction Pharmacotherapy is one of the main treatments for patients with young-onset Parkinson’s disease (YOPD). Although numerous studies on the treatment of YOPD have been published, the real-world prescription patterns of these populations r
Externí odkaz:
https://doaj.org/article/b2996c58c5684e26b3650695da77659b
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundAll agents engaging sphongosine-1-phospate receptors (S1PRs) will have some cardiovascular effect. This study aimed to elucidate the risk of cardiovascular adverse events (AEs) in patients with multiple sclerosis (MS) treated with S1PR modu
Externí odkaz:
https://doaj.org/article/a7cefa9f1a63435986d6382c94cfe2c9
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Background and Aims: There is a controversy regarding whether fingolimod is associated with an increased risk of infection in patients with multiple sclerosis (MS). We performed a systematic review and meta-analysis of data from randomized controlled
Externí odkaz:
https://doaj.org/article/105bd9c860304ec6b1445d8df88386c6
Autor:
Zi‐ran Li, Rui‐dong Li, Wan‐jie Niu, Xin‐yi Zheng, Zheng‐xin Wang, Ming‐kang Zhong, Xiao‐yan Qiu
Publikováno v:
The Journal of Clinical Pharmacology. 63:314-325
This study aimed to develop and evaluate a population pharmacokinetic (PPK) combined machine learning approach to predict tacrolimus trough concentrations for Chinese adult liver transplant recipients in the early post-transplant period. Tacrolimus t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4511cdbac9f15934ed99671208223a0e
https://doi.org/10.1002/jcph.2156
https://doi.org/10.1002/jcph.2156
Publikováno v:
Expert Opinion on Drug Safety. :1-9
Panoramic views of post-marketing safety profiles, such as cancer signal, of phosphodiesterase 5A (PDE5A) inhibitors have yet to be fully evaluated.Data from the FDA Adverse Event Reporting System (FAERS) concerning the timeframe between January 1Sil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89db87aed46092354de936cea5a58629
https://doi.org/10.1080/14740338.2023.2145280
https://doi.org/10.1080/14740338.2023.2145280
Autor:
Xiao-Qin, Liu, Yu-Fei, Zhang, Hong-Yan, Ding, Ming-Ming, Yan, Zheng, Jiao, Ming-Kang, Zhong, Chun-Lai, Ma
Publikováno v:
Acta Pharmacologica Sinica. 43:2723-2734
Rivaroxaban, a direct factor Xa inhibitor, is widely used for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to conduct a population pharmacokinetic-pharmacodynamic (PK-PD) analysis of rivaroxaba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10cbb577c51b8c67c87d86d41df1a701
https://doi.org/10.1038/s41401-022-00892-9
https://doi.org/10.1038/s41401-022-00892-9